Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Novartis AG ADS (NY: NVS)
74.36 USD  +0.54 (+0.73%)
Official Closing Price  /  Updated: 6:40 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
Blog posts about Novartis AG ADS
 
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Incyte In Neutral Lane
February 10, 2012
We are maintaining our Neutral recommendation on Incyte Corporation (NASDAQ:INCY) with a target price of $18.00. Incyte is a Wilmington, Delaware-based drug discovery and development company focused on... Read More
category NVS , INCY , Stocks , and 3 more.
from DailyMarkets.com
Generic Challenge For UTHR’s Remodulin
February 08, 2012
United Therapeutics Corporation (NASDAQ:UTHR) is facing a patent challenge for its lead product, Remodulin (treprostinil) injection. Sandoz, Novartis’ (NYSE:NVS) generic unit, is seeking approval for... Read More
category NVS , UTHR , Stocks , and 4 more.
from DailyMarkets.com
Is Novartis Reversing?
February 02, 2012
New York, February 2nd (TradersHuddle.com) - Shares of Novartis AG ( NYSE:NVS ) closed the trading day higher by $1.13 or 2.08% from its previous close. Novartis' shares price action formed what is... Read More
from TradersHuddle.com
Risk-Reward Balances For Endo Pharma
February 01, 2012
We are maintaining our Neutral stance on Endo Pharmaceuticals (NASDAQ:ENDP) with a target price of $39.00. Endo Pharma is a specialty healthcare solutions company that operates in the US and offers... Read More
category NVS , ENDP , Stocks , and 2 more.
from DailyMarkets.com
EPS Beat For Biogen; Outlook Weak
January 31, 2012
Biogen Idec (NASDAQ:BIIB) reported fourth-quarter earnings per share of $1.51, well above the Zacks Consensus Estimate of $1.46 and the year-ago earnings of $1.41. Fourth quarter results were boosted... Read More
category NVS , RHHBY , ELN , and 4 more.
from DailyMarkets.com
Biogen & Elan Announce Tysabri Trial
January 30, 2012
Biogen Idec (NASDAQ:BIIB) and Elan Corporation, plc (NYSE:ELN) recently announced that they are conducting a phase III study of Tysabri for secondary-progressive multiple sclerosis (“SPMS”). The phase... Read More
category NVS , ELN , Stocks , and 3 more.
from DailyMarkets.com
NVS Beats By A Penny, View Guarded
January 27, 2012
Swiss pharmaceutical giant Novartis (NYSE:NVS) reported earnings per share of $1.23 for the fourth quarter of 2011, marginally beating the Zacks Consensus Estimate of $1.22. Earnings were also above... Read More
category Stocks , External Research , Contributor
from DailyMarkets.com
Novartis Drugs Backed By CHMP
January 25, 2012
Novartis (NYSE:NVS) recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) rendered positive opinion for two of its drugs. First, the... Read More
category NVS , Stocks , External Research , and 1 more.
from DailyMarkets.com
Reasons To Stay Interested In SNWV
January 25, 2012
Reasons To Stay Interested in SNWV Brian Marckx, CFA We met with SANUWAVE’s (SNWV) management at the J.P. Morgan Healthcare conference in San Francisco earlier this month and were encouraged by their... Read More
category NVS , SHPGY , Stocks , and 2 more.
from DailyMarkets.com
Mylan Outperforms As Generics Rule
January 24, 2012
We recently upgraded our recommendation on Mylan, Inc. (NYSE:MYL) from Neutral to Outperform with a target price of $26.00. Mylan is one of the leading players in the US generics market. We are... Read More
category NVS , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Trading Idea - Entry Levels for Novartis
January 23, 2012
New York, January 23rd (TradersHuddle.com) - Shares of Novartis AG ( NYSE:NVS ) are trading very close to calculated support at $54.95 with current price action closing at just $55.73 places the stock... Read More
from TradersHuddle.com
(BIIB) Biogen Analyst Neutral on Shares
January 21, 2012
We recently reiterated our Neutral recommendation on Biogen Idec (BIIB). Biogen is the market... Visit StockBlogHub to view complete post. Read More
category PML , Biotechnology , PIMCO Municipal Income Fund II , and 11 more.
from Stock Blog Hub
Neutral On Biogen
January 20, 2012
We recently reiterated our Neutral recommendation on Biogen Idec (NASDAQ:BIIB). Biogen is the market leader in therapies for the treatment of multiple sclerosis (MS). We believe the company will... Read More
category NVS , SNY , Stocks , and 4 more.
from DailyMarkets.com
Hot Option Plays: Look At The Irish
January 20, 2012
Cusick’s Corner 01-20-2012 “Look at the Irish.” With the market staying in a tight but choppy range this expiration, I had a little extra time today and checked out how the Irish stock market has been... Read More
category MPEL , goog , Options , and 15 more.
from DailyMarkets.com
WARNING - Europe is Already Costing the U.S. Economy
January 17, 2012
category Europe , Editors/Picks/01/12 , Editors/Picks , and 2 more.
from Wall Street Greek
Novartis To Cut Jobs
January 17, 2012
Continuing the cost-cutting trend which was started by its US counterparts, Swiss company Novartis (NYSE:NVS) recently announced that it will lay off 1,960 employees in the US in anticipation of lower... Read More
category NVS , Stocks , External Research , and 1 more.
from DailyMarkets.com
Biosimilars: The Next Big Thing
January 13, 2012
As a large number of branded biopharmaceuticals/biologics are slated to lose patent protection in the US and other markets, generic companies like Hospira, Inc. (NYSE:HSP), Teva Pharmaceuticals... Read More
category RHHBY , TEVA , External Research , and 9 more.
from DailyMarkets.com
Change At Teva’s Helm
January 05, 2012
Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) recently announced a leadership change with current President and CEO, Shlomo Yanai, expected to retire from the company effective May 2012. Mr. Yanai... Read More
category NVS , TEVA , Stocks , and 3 more.
from DailyMarkets.com
Regeneron Settles Dispute
January 04, 2012
Recently, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reached a non-exclusive license and partial settlement agreement with Genentech, Inc. {a wholly owned subsidiary of Roche (RHHBY)} regarding the... Read More
category NVS , RHHBY , REGN , and 3 more.
from DailyMarkets.com
Above Resistance - Novartis
January 02, 2012
New York, January 2nd (TradersHuddle.com) - Shares of Novartis AG ( NYSE:NVS ) closed the trading session at $57.17 just above calculated resistance at $57.16 effectively breaking out, grabbing the... Read More
from TradersHuddle.com
Novartis Close to Resistance
December 30, 2011
New York, December 30th (TradersHuddle.com) - Shares of Novartis AG ( NYSE:NVS ) are trading very close to calculated resistance at $57.16 with the current price action closing at just $56.84 placing... Read More
from TradersHuddle.com
Ring In Generics In 2012 And Beyond
December 29, 2011
The New Year is expected to be a happy beginning for generic companies like Teva Pharmaceuticals (NASDAQ:TEVA), Mylan, Inc. (NYSE:MYL), Watson Pharma (NYSE:WPI), Dr. Reddy’s (NYSE:RDY) and Sandoz, the... Read More
category TEVA , FRX , External Research , and 12 more.
from DailyMarkets.com
More Generic Launches For Mylan
December 28, 2011
Generic maker, Mylan Inc. (NYSE:MYL) received final approval from the US Food & Drug Administration (FDA) to launch its generic versions of Abbott Laboratories’ (NYSE:ABT) hypertension tablets Teveten... Read More
category NVS , TEVA , WPI , and 6 more.
from DailyMarkets.com
Sanofi’s Multiple Sclerosis Drug Disappoints
December 23, 2011
Sanofi’s (NYSE:SNY) subsidiary, Genzyme, recently announced disappointing top-line results of its phase III candidate, Aubagio (teriflunomide). Results were presented from the phase III TENERE trial,... Read More
category NVS , MKGAF , SNY , and 4 more.
from DailyMarkets.com
Call Volume Rises on Novartis, Despite Drug Snafu
December 20, 2011
Call players have taken notice of pharmaceutical giant Novartis AG (NVS - 56.21) in the options pits today, as nearly 3,500 of these options have changed hands so far, representing eight times the... Read More
category NVS
from SchaeffersResearch.com Daily Market Blog
Hot Option Plays: Defense, Defense
December 13, 2011
Cusick’s Corner While agreements in kind came out of the meetings last week in the EU, EU bond markets (specifically Spain & Italy) are not confirming the positive tone that was resonating in the... Read More
category RIMM , Options , ADBE , and 12 more.
from DailyMarkets.com
Hot Option Plays: Weak Hands Rule The Market
December 13, 2011
Cusick’s Corner Nice volatile move, S&Ps giving back all of the gain from Friday, but what made me feel a little better about this most recent pullback is that there was no reaction in the VIX and it... Read More
category Options , LUV , ATVI , and 11 more.
from DailyMarkets.com
(NVS) Novartis’ Cancer Drug Afinitor Shows Promise for Breast Cancer
December 12, 2011
Novartis’ (NVS) cancer drug Afinitor took a significant step forward, as the company once again... Visit StockBlogHub to view complete post. Read More
category TS , HCC , Tenaris SA , and 15 more.
from Stock Blog Hub
Positive Data On Novartis’ Afinitor
December 12, 2011
Novartis’ (NYSE:NVS) cancer drug Afinitor took a significant step forward, as the company once again presented encouraging data from late-stage trials of Afinitor for the treatment of breast cancer, an... Read More
category AZN , RHHBY , External Research , and 5 more.
from DailyMarkets.com
Cooper Beats, Profits Rise
December 09, 2011
The Cooper Companies (NYSE:COO), a company dedicated to contact lens and women’s health, reported fourth-quarter fiscal 2011 (ended October 31) results with adjusted earnings per share of $1.46... Read More
category NVS , jnj , COO , and 3 more.
from DailyMarkets.com
< Previous 1 2 3 4 5 6 7 8 9
...
27 28 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here